The Oxford Antibiotic Group has outstanding expertise in drug development, and a large number of screening platforms for various indications. In addition OxAG is the only company in Central Europe that operates a high throughput C. elegans screening platform to investigate effect and toxicology.
In addition to OxAG’s in house research programs, the company operates a CRO business, which gives academic and industrial collaborators access to the platforms.
The services that are being offered, are as follows:
Medicinal chemistry and synthesis
Compound modification based on medicinal chemistry aspects to improve solubility, stability or ADME features. We deliver the full project process by developing with the partner the synthesis concept and the screening based med-chem. program.
With more than 140 different MDR bacteria, fungi and virus, our EUCAST standardized anti-infective screening is delivered in 96 well format. The expertise of the international team guarantees the best results for your screening activities.
Additionally to the C. elegans based antibiotic screening we offer C. elegans models for age associated neurodegenerative disorders (Alzheimer´s disease, Parkinson´s diseases, Huntington disease and amyotrophic lateral sclerosis).
One of our core contractual platforms is toxicological screening. In this platform, we deliver broad toxicological screening platform in HTS to check general toxicity (Alamar Blue, AnnexinV/PI, Caspase, MTT-Assay, hERG-Test) and genotox/mutagenic (HPRT Assay, Comet Assay, Micronucleus Assay, Mitotic index) activity of compounds.
In addition, our C.elegans-based toxicity platform is designed to give an indication of toxicity potential early in the product development pipeline in order to eliminate high-risk compounds without the need for testing on vertebrates.